Q2QLE0
PR
Gene name |
MET |
Protein name |
Hepatocyte growth factor receptor |
Names |
HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met |
Species |
Sus scrofa (Pig) |
KEGG Pathway |
ssc:654328 |
EC number |
2.7.10.1: Protein-tyrosine kinases |
Protein Class |
|
Descriptions
(Annotation based on sequence homology with Q12866)
Tyrosine-protein kinase Mer (MerTK, Mer) is a transmembrane tyrosine receptor kinase with extracellular immunoglobulin and fibronectin-like domains that recognize ligands such as growth arrest specific 6 (Gas6) and protein S. Ligand-binding leads to autophosphorylation of the tyrosine in the activation loop (Tyr749, Tyr753 and Tyr754) and then results in the activation of downstream enzymes (PI3K, MAPK, GTPase).
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
1221-1248 (Activation loop from InterPro)
Target domain |
1078-1345 (Protein kinase domain) |
Relief mechanism |
|
Assay |
|
Autoinhibited structure
Activated structure
1 structures for Q2QLE0
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q2QLE0-F1 | Predicted | AlphaFoldDB |
32 variants for Q2QLE0
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs708981854 | 17 | T>I | No | EVA | |
| rs704020570 | 91 | E>* | No | EVA | |
| rs713888024 | 109 | G>V | No | EVA | |
| rs3474594741 | 111 | I>V | No | EVA | |
| rs712309422 | 228 | K>M | No | EVA | |
| rs698290936 | 238 | V>F | No | EVA | |
| rs690102556 | 285 | V>I | No | EVA | |
| rs699897946 | 286 | D>N | No | EVA | |
| rs792323165 | 351 | K>Q | No | EVA | |
| rs692461475 | 352 | P>S | No | EVA | |
| rs325071795 | 495 | P>T | No | EVA | |
| rs699494606 | 537 | Q>E | No | EVA | |
| rs709352856 | 567 | K>N | No | EVA | |
| rs697344182 | 586 | W>C | No | EVA | |
| rs706990397 | 590 | F>L | No | EVA | |
| rs711425116 | 622 | L>F | No | EVA | |
| rs694223130 | 624 | C>F | No | EVA | |
| rs709085349 | 729 | A>S | No | EVA | |
| rs322793417 | 776 | V>I | No | EVA | |
| rs698631015 | 804 | P>T | No | EVA | |
| rs712834176 | 827 | H>R | No | EVA | |
| rs703200463 | 841 | F>L | No | EVA | |
| rs701391478 | 889 | S>F | No | EVA | |
| rs321467113 | 900 | L>V | No | EVA | |
| rs705289092 | 949 | L>I | No | EVA | |
| rs713871434 | 970 | R>H | No | EVA | |
| rs704054814 | 974 | R>I | No | EVA | |
| rs791143341 | 1074 | S>N | No | EVA | |
| rs709838358 | 1075 | S>R | No | EVA | |
| rs704736587 | 1091 | C>F | No | EVA | |
| rs697080819 | 1229 | V>M | No | EVA | |
| rs699218960 | 1377 | G>C | No | EVA |
No associated diseases with Q2QLE0
12 regional properties for Q2QLE0
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Protein kinase domain | 1078 - 1345 | IPR000719 |
| domain | Serine-threonine/tyrosine-protein kinase, catalytic domain | 1078 - 1336 | IPR001245 |
| domain | Sema domain | 27 - 515 | IPR001627 |
| repeat | Plexin repeat | 520 - 561 | IPR002165 |
| domain | IPT domain | 562 - 655 | IPR002909-1 |
| domain | IPT domain | 656 - 739 | IPR002909-2 |
| domain | IPT domain | 741 - 836 | IPR002909-3 |
| domain | IPT domain | 838 - 934 | IPR002909-4 |
| active_site | Tyrosine-protein kinase, active site | 1200 - 1212 | IPR008266 |
| domain | PSI domain | 519 - 562 | IPR016201 |
| binding_site | Protein kinase, ATP binding site | 1084 - 1110 | IPR017441 |
| domain | Tyrosine-protein kinase, catalytic domain | 1078 - 1337 | IPR020635 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.10.1 | Protein-tyrosine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| basal plasma membrane | The region of the plasma membrane located at the basal end of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
6 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| hepatocyte growth factor receptor activity | Combining with hepatocyte growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. |
| identical protein binding | Binding to an identical protein or proteins. |
| protein phosphatase binding | Binding to a protein phosphatase. |
| semaphorin receptor activity | Combining with a semaphorin, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| transmembrane receptor protein tyrosine kinase activity | Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate. |
22 GO annotations of biological process
| Name | Definition |
|---|---|
| branching morphogenesis of an epithelial tube | The process in which the anatomical structures of branches in an epithelial tube are generated and organized. A tube is a long hollow cylinder. |
| cell migration | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms. |
| endothelial cell morphogenesis | The change in form (cell shape and size) that occurs during the differentiation of an endothelial cell. |
| establishment of skin barrier | Establishment of the epithelial barrier, the functional barrier in the skin that limits its permeability. |
| liver development | The process whose specific outcome is the progression of the liver over time, from its formation to the mature structure. The liver is an exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes. |
| negative regulation of guanyl-nucleotide exchange factor activity | Any process that stops, prevents or reduces the frequency, rate or extent of guanyl-nucleotide exchange factor activity. |
| negative regulation of hydrogen peroxide-mediated programmed cell death | Any process that stops, prevents or reduces the frequency, rate or extent of hydrogen peroxide-mediated programmed cell death. |
| negative regulation of Rho protein signal transduction | Any process that stops, prevents, or reduces the frequency, rate or extent of Rho protein signal transduction. |
| negative regulation of stress fiber assembly | Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly a stress fiber, a bundle of microfilaments and other proteins found in fibroblasts. |
| negative regulation of thrombin-activated receptor signaling pathway | Any process that stops, prevents, or reduces the frequency, rate or extent of thrombin-activated receptor protein signaling pathway activity. A thrombin receptor signaling pathway is the series of molecular signals generated as a consequence of a thrombin-activated receptor binding to one of its physiological ligands. |
| nervous system development | The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state. |
| neuron differentiation | The process in which a relatively unspecialized cell acquires specialized features of a neuron. |
| pancreas development | The process whose specific outcome is the progression of the pancreas over time, from its formation to the mature structure. The pancreas is an endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating enzymes. |
| phagocytosis | A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles. |
| positive chemotaxis | The directed movement of a motile cell or organism towards a higher concentration of a chemical. |
| positive regulation of endothelial cell chemotaxis | Any process that activates or increases the frequency, rate or extent of endothelial cell chemotaxis. |
| positive regulation of kinase activity | Any process that activates or increases the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule. |
| positive regulation of microtubule polymerization | Any process that activates or increases the frequency, rate or extent of microtubule polymerization. |
| positive regulation of protein kinase B signaling | Any process that activates or increases the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| semaphorin-plexin signaling pathway | The series of molecular signals generated as a consequence of a semaphorin receptor (composed of a plexin and a neurophilin) binding to a semaphorin ligand. |
| transmembrane receptor protein tyrosine kinase signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription. |
41 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q769I5 | MET | Hepatocyte growth factor receptor | Bos taurus (Bovine) | PR |
| A0M8S8 | MET | Hepatocyte growth factor receptor | Felis catus (Cat) (Felis silvestris catus) | PR |
| Q75ZY9 | MET | Hepatocyte growth factor receptor | Canis lupus familiaris (Dog) (Canis familiaris) | PR |
| Q2QLA9 | MET | Hepatocyte growth factor receptor | Equus caballus (Horse) | PR |
| O43157 | PLXNB1 | Plexin-B1 | Homo sapiens (Human) | EV SS |
| Q9HCM2 | PLXNA4 | Plexin-A4 | Homo sapiens (Human) | SS |
| O75051 | PLXNA2 | Plexin-A2 | Homo sapiens (Human) | SS |
| P51805 | PLXNA3 | Plexin-A3 | Homo sapiens (Human) | SS |
| Q9UIW2 | PLXNA1 | Plexin-A1 | Homo sapiens (Human) | EV SS |
| O15031 | PLXNB2 | Plexin-B2 | Homo sapiens (Human) | SS |
| Q9ULL4 | PLXNB3 | Plexin-B3 | Homo sapiens (Human) | SS |
| Q04912 | MST1R | Macrophage-stimulating protein receptor | Homo sapiens (Human) | EV |
| P08581 | MET | Hepatocyte growth factor receptor | Homo sapiens (Human) | EV |
| P34925 | RYK | Tyrosine-protein kinase RYK | Homo sapiens (Human) | PR |
| Q12866 | MERTK | Tyrosine-protein kinase Mer | Homo sapiens (Human) | EV |
| Q06418 | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Homo sapiens (Human) | SS |
| P30530 | AXL | Tyrosine-protein kinase receptor UFO | Homo sapiens (Human) | PR |
| Q9QY40 | Plxnb3 | Plexin-B3 | Mus musculus (Mouse) | SS |
| P70208 | Plxna3 | Plexin-A3 | Mus musculus (Mouse) | EV SS |
| Q3UH93 | Plxnd1 | Plexin-D1 | Mus musculus (Mouse) | SS |
| P70207 | Plxna2 | Plexin-A2 | Mus musculus (Mouse) | SS |
| B2RXS4 | Plxnb2 | Plexin-B2 | Mus musculus (Mouse) | SS |
| Q8CJH3 | Plxnb1 | Plexin-B1 | Mus musculus (Mouse) | SS |
| Q9QZC2 | Plxnc1 | Plexin-C1 | Mus musculus (Mouse) | SS |
| Q80UG2 | Plxna4 | Plexin-A4 | Mus musculus (Mouse) | SS |
| P70206 | Plxna1 | Plexin-A1 | Mus musculus (Mouse) | EV SS |
| Q62190 | Mst1r | Macrophage-stimulating protein receptor | Mus musculus (Mouse) | SS |
| Q01887 | Ryk | Tyrosine-protein kinase RYK | Mus musculus (Mouse) | PR |
| Q00993 | Axl | Tyrosine-protein kinase receptor UFO | Mus musculus (Mouse) | PR |
| P55144 | Tyro3 | Tyrosine-protein kinase receptor TYRO3 | Mus musculus (Mouse) | SS |
| Q60805 | Mertk | Tyrosine-protein kinase Mer | Mus musculus (Mouse) | SS |
| P16056 | Met | Hepatocyte growth factor receptor | Mus musculus (Mouse) | PR |
| P24786 | NTRK3 | NT-3 growth factor receptor | Sus scrofa (Pig) | SS |
| Q2HWD6 | KIT | Mast/stem cell growth factor receptor Kit | Sus scrofa (Pig) | SS |
| D3ZPX4 | Plxna3 | Plexin-A3 | Rattus norvegicus (Rat) | SS |
| D3ZLH5 | Plxnb3 | Plexin-B3 | Rattus norvegicus (Rat) | SS |
| P97523 | Met | Hepatocyte growth factor receptor | Rattus norvegicus (Rat) | PR |
| P57097 | Mertk | Tyrosine-protein kinase Mer | Rattus norvegicus (Rat) | SS |
| H2KZU7 | svh-2 | Tyrosine-protein kinase receptor svh-2 | Caenorhabditis elegans | SS |
| Q6BEA0 | plxna4 | Plexin-A4 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| B0S5N4 | plxna3 | Plexin A3 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MKAPAVLAPG | ILVLLFTLVQ | KSKGECKEAL | VKSTMNLNMQ | YQLPNFTAET | PIQNVVLHKH |
| 70 | 80 | 90 | 100 | 110 | 120 |
| HIYLGALNYI | YVLNDIDLRK | VAEYKTGPVL | EHPDCFPCQD | CSHKANLSGG | IWRDNINMAL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LVDTYYDDQL | ISCGSVHRGT | CQRHVLPPDN | IADIKSEVHC | MYSPQVDEEP | SQCPDCVVSA |
| 190 | 200 | 210 | 220 | 230 | 240 |
| LGTKVLLSEK | DRFINFFVGN | TINSSYLPDH | SLHSISVRRL | KETQDGFKFL | TDQSYIDVLP |
| 250 | 260 | 270 | 280 | 290 | 300 |
| EFRDSYPIKY | VHAFESNHFI | YFLTVQRETL | DAQTFHTRII | RFCSVDSGLH | SYMEMPLECI |
| 310 | 320 | 330 | 340 | 350 | 360 |
| LTEKRRKRST | REEVFNILQA | AYVSKPGTQL | AKQIGANLND | DILYGVFAQS | KPDSAEPMNR |
| 370 | 380 | 390 | 400 | 410 | 420 |
| SAVCAFPVKY | VNEFFNKIVN | KNNVRCLQHF | YGPNHEHCFN | RTLLRNSSGC | EVRSDEYRTE |
| 430 | 440 | 450 | 460 | 470 | 480 |
| FTTALQRIDL | FMGQFNQVLL | TSISTFIKGD | LTIANLGTSE | GRFMQVVVSR | PGLSTPHVNF |
| 490 | 500 | 510 | 520 | 530 | 540 |
| HLDSHPVSPE | VIVEPLNQNG | YTLVVTGKKI | TKIPLNGLGC | EHFQSCSQCL | SAPPFVQCGW |
| 550 | 560 | 570 | 580 | 590 | 600 |
| CQDKCVQLEE | CPSGTWTQEI | CLPTVYKVFP | TSAPLEGGTT | LTICGWDFGF | RRNNKFDLRK |
| 610 | 620 | 630 | 640 | 650 | 660 |
| TKVLLGNESC | TLTLSESTTN | TLKCTVGPAM | NEHFNMSIVI | SNGRGTTQYR | TFSYVDPVIT |
| 670 | 680 | 690 | 700 | 710 | 720 |
| NISPSFGPKT | GGTLLTLTGM | HLNSGNSRHI | SIGGKTCTLK | SVSDSILECY | TPAQTTPTEF |
| 730 | 740 | 750 | 760 | 770 | 780 |
| PIKLKIDLAN | REINSFTYRE | DPIVYEIHPT | KSFISGGSTI | TGVGRNLNSV | SVLRMVINVH |
| 790 | 800 | 810 | 820 | 830 | 840 |
| EAERNFTVAC | QHRSNSEIIC | CTTPSLQQLN | LQLPLKTKAF | FMLDGIHSKY | FDLIYVHNPV |
| 850 | 860 | 870 | 880 | 890 | 900 |
| FKPFEKPVMI | SIGNENVLEI | KGNDIDPEAV | KGEVLKVGNK | SCENIHSHSE | AVLCTVPNDL |
| 910 | 920 | 930 | 940 | 950 | 960 |
| LKLNSELNIE | WKQAISSTVL | GKVIVQPDQN | FTGLIVGVVS | ISIILLLLLG | LFLWLKKRKQ |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| IKDLGSELVR | YDARVHTPHL | DRLVSARSVS | PTTEMVSSEP | VDYRATFPED | QFPNSSQNGS |
| 1030 | 1040 | 1050 | 1060 | 1070 | 1080 |
| CRQVQYPLTD | LSPILTSGDS | DISSPLLQNT | VHIDLSALNP | ELVQAVQHVV | IGPSSLIVHF |
| 1090 | 1100 | 1110 | 1120 | 1130 | 1140 |
| NEVIGRGHFG | CVYHGTLLDN | DDKKIHCAVK | SLNRITDIGE | VSQFLTEGII | MKDFSHPNVL |
| 1150 | 1160 | 1170 | 1180 | 1190 | 1200 |
| SLLGICLRSE | GSPLVVLPYM | KHGDLRNFIR | NETHNPTVKD | LIGFGLQVAK | GMKYLASKKF |
| 1210 | 1220 | 1230 | 1240 | 1250 | 1260 |
| VHRDLAARNC | MLDEKFTVKV | ADFGLARDVY | DKEYYSVHNK | TGAKLPVKWM | ALESLQTQKF |
| 1270 | 1280 | 1290 | 1300 | 1310 | 1320 |
| TTKSDVWSFG | VLLWELMTRG | APPYPDVNTF | DITVYLLQGR | RLLQPEYCPD | PLYEVMLKCW |
| 1330 | 1340 | 1350 | 1360 | 1370 | 1380 |
| HPRAELRPSF | SELVSRISAI | FSTFIGEHYV | HVNATYVNVK | CVAPYPSLLS | SQDNVDGEGD |
| T |